MedTrace Logo

Serotonergic Modulation of Cognition, Emotion and Brain Activation in Healthy Volunteers

NCT04239339 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2023-11-18

No results posted yet for this study

Summary

The aim of this project is:

* To apply a pharmacological tool of selective serotonin (5-hydroxytryptamine, 5-HT system) reuptake inhibition in healthy humans. Specifically:
* To investigate how sub-chronic administration of 20 mg of escitalopram affects cognitive performance ('cold' cognition) and social-emotional functioning ('hot' cognition) compared with placebo; and
* To investigate how sub-chronic administration of 20 mg of escitalopram affects functional brain activation during a paradigm of reinforcement learning following drug administration compared with placebo, and how activation relates to cognitive performance and social-emotional functioning.

Conditions

  • Healthy

Interventions

DRUG

Escitalopram 20 mg

20mg daily for approximately 3 weeks.

DRUG

Placebo

Placebo daily for approximately 3 weeks.

Sponsors & Collaborators

  • University of Cambridge

    collaborator OTHER

  • Lundbeck Foundation

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-28
Primary Completion
2022-10-30
Completion
2022-10-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04239339 on ClinicalTrials.gov